PDCD1 and hypothyroidism: CTLA-4 inhibitors cause hypothyroidism in 2.5-5.2% of the patients, while PD-1/PD-L1 inhibitors affect 3.9-8.5% and combinations of ICIs are responsible for 10.2-16.4% of the cases (96, 97, 153).